Table 3.

Summary of pregnancy outcomes

Maternal age group, years	Serious adverse event	Time since sotrovimab treatment	Potential considerations (confounding factors and timing)
Maternal events
26–30	Prolonged labor	–a	Obesity, nulliparity
31–35	–	–	–
36–40	Pre-eclampsia	163 days	Unspecified disability, overweight, tobacco use, temporal relationship
	Polyhydramnios	60 days	–
	Premature labor	105 days	PCOS, obesity, tobacco use
Infant/fetal events
26–30	Fetal cardiac disorder	90 days	Obesity, recreational drug use; relationship to treatment not assessable due to insufficient data
	Congenital ankyloglossia	73 days	Temporal relationship not suggestive of treatment causality
31–35	Persistent right umbilical vein, congenital ankyloglossia	59 days	Temporal relationship not suggestive of treatment causality
	Congenital hydronephrosis	185 days	Temporal relationship not suggestive of treatment causality; lack of plausible mechanism

PCOS polycystic ovary syndrome

^aNo information available on the timing of sotrovimab administration